Drugs / LV305
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02387125 | Feb 2015 → Mar 2019 | melanoma, non-small cell lung carcinoma, ovarian cancer, sarcoma | Immune Design | Terminated | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02609984 | Apr 2015 → Feb 2019 | myxoid/round cell liposarcoma, synovial sarcoma | Immune Design | Terminated | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03520959 | Sep → Nov 2018 | synovial sarcoma | Immune Design | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV305 | “CMB305 (sequentially administered LV305 which is a dendritic cell-targeting viral vector expressing the New York Esophageal Squamous Cell Carcinoma 1 gene” NCT02609984 ↗2“where intradermal LV305 is administered sequentially with intramuscular G305 over three months” NCT02387125 ↗ |